ALK-Abelló A/S, a pharmaceutical company, develops, manufactures, and sells a range of products for the diagnosis and treatment of respiratory diseases worldwide. The company offers allergy immunotherapy products, such as subcutaneous injections under the Alutard SQ and AVANZ brand names; sublingual drops under the SLIToneULTRA and Osiris brand names; and sublingual tablets under the GRAZAX/GRASTEK, RAGWITEK, and ACARIZAX/MITICURE brand names. Its allergy immunotherapy products are used for treating various allergies, including grass, ragweed, house dust mite, tree, Japanese cedar, and cat, as well as bee and wasp venom. The company also offers adrenaline auto-injectors for the treatment of severe allergic reactions. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.
alk-abello a/s (AKBLF:OTC US)
Bøge Allé 6-8
Phone: 45 45 74 75 76
Fax: 45 45 74 86 90www.alk-abello.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for AKBLF.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.